Telemedicine Platform Faces Heat from Feds and Pharma

Hims & Hers, a major telemedicine platform, is in trouble for selling compounded GLP-1 medications. The federal government and a big drugmaker are breathing down their necks. It’s not looking good for the company.

What’s Going On?

The issue is with Hims & Hers’ sales of popular GLP-1 meds, which are usually used to treat type 2 diabetes. The problem is, they’re being prescribed for weight loss, and that’s not exactly what they’re approved for. The feds and the drugmaker are calling foul, saying Hims & Hers is playing fast and loose with the rules.

It’s a pretty ridiculous situation, if you ask me. I mean, who doesn’t know that using diabetes meds for weight loss is a bad idea? It’s not like Hims & Hers is trying to hide it, either – they’re just doing it out in the open, like they think they’re above the law or something.